Hospital Quality Independently Impacts Readmission Rates

Share this content:
Hospital Quality Independently Impacts Readmission Rates
Hospital Quality Independently Impacts Readmission Rates

FRIDAY, Sept. 15, 2017 (HealthDay News) -- Hospital quality contributes to readmission rates independent of factors involving patients, according to a study published in the Sept. 14 issue of the New England Journal of Medicine.

Harlan M. Krumholz, M.D., from the Yale-New Haven Hospital in Connecticut, and colleagues divided the Centers for Medicare & Medicaid Services hospital-wide readmission measure cohort into two random samples. The first was used to calculate the risk-standardized readmission rate within 30 days for each hospital, with hospitals classified into performance quartiles. The study sample identified from the second sample included patients with two admissions for similar diagnoses at different hospitals. Readmission rates were compared among patients who had been admitted to hospitals in different performance quartiles.

The researchers found that the median risk-standardized readmission rate was 15.5 percent in the performance-classification sample. In the study sample (37,508 patients with two admissions for similar diagnoses at 4,272 different hospitals), the observed readmission rate was higher for patients admitted to hospitals in a worse-performing versus a better-performing quartile. The only significant difference was seen when patients were admitted to hospitals in which one was in the best-performing and one in the worst-performing quartile (absolute difference in readmission rate, 2.0 percentage points).

"The findings suggest that hospital quality contributes in part to readmission rates independent of factors involving patients," the authors write.

Abstract/Full Text (subscription or payment may be required)

Share this content:

is free, fast, and customized just for you!

Already a member?

Sign In Now »

Drug Lookup

Browse drugs by: BrandGenericDisease

Trending Activities

All Professions


Sign up for myCME e-newsletters


More in Home

FDA OKs Nucala for Eosinophilic Granulomatosis With Polyangiitis

FDA OKs Nucala for Eosinophilic Granulomatosis With Polyangiitis

First drug to be approved for rare autoimmune disease that leads to vasculitis

Findings Support Individualized Glycemic Control in T2DM

Findings Support Individualized Glycemic Control in T2DM

Approach saved $13,547/patient vs uniform intensive control, with lower medication costs

Atherosclerosis ID'd in Many Without CV Risk Factors

Atherosclerosis ID'd in Many Without CV Risk Factors

LDL-C independently associated with the presence and extent of atherosclerosis

is free, fast, and customized just for you!

Already a member?

Sign In Now »